1 of 1
Story summary
- University of California, San Diego (UC San Diego) researchers show that combining proteasome inhibitors with Lys05 reduces acute myeloid leukemia cell growth and improves survival in preclinical models.
- The study finds AML cells can evade proteasome inhibitors by activating backup survival pathways.
- The researchers plan to advance these combination therapies into clinical trials, pursuing mutation-agnostic strategies.
- If successful, the approach could reshape AML treatment and improve patient outcomes.
